WYNN's fourth-quarter 2024 performance reflects strong contributions from Wynn Palace and Las Vegas Operations.

ATUS reported a top-line contraction year over year in the fourth quarter of 2024, owing to declining net sales in multiple segments.

MRNA's earnings and revenues surpass estimates in the fourth quarter of 2024. The company reiterates 2025 total revenue guidance.

SAH's fourth-quarter earnings and sales surpass the Zacks Consensus Estimate. However, earnings decline year over year.

ATR's Q4 top line gains from improved performances of the Pharma and Closures segments.

Robust segmental performances benefit RSG's top line in the fourth quarter of 2024.

ZBRA's fourth-quarter 2024 revenues surge 32.2% year over year, driven by strength in the Asset Intelligence & Tracking and Enterprise Visibility &...

ENB Q4 earnings and revenues beat estimates, driven by higher Adjusted EBITDA contributions across its key business segments. Revenues also increase...

While a robust demand environment and contribution from the Venafi acquisition drive CYBR's Q4 top-line growth, lower expenses boost the bottom line.

COOP's fourth-quarter 2024 results benefit from solid growth in the Servicing and Originations segments. A rise in expenses acts as a spoilsport.